CyberKnife Technology For Cancer Treatment Introduced At Tawam Hospital, First In The UAE
In a first in the UAE, PureHealth has unveiled the CyberKnife technology at Tawam Hospital, a SEHA facility within its network. This introduction marks the first deployment of such technology in Abu Dhabi, reinforcing the emirate's status as a leading healthcare hub globally. This advancement signifies a notable step for the healthcare system in the region.
CyberKnife technology is designed to treat a variety of tumours, both cancerous and non-cancerous. It is effective against brain and spinal tumours, as well as lung, liver, prostate, and pancreas cancers. Additionally, it addresses complex and recurrent head and neck cancers, alongside non-cancerous conditions like trigeminal neuralgia and arteriovenous malformations.
Utilising the advanced CyberKnife S7 system, Tawam Hospital now offers the UAE's most sophisticated non-invasive radiotherapy solution. This technology represents a significant advancement in cancer treatment in the region, using precise robotic systems to deliver innovative solutions that notably enhance patient outcomes and improve quality of life.
Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, emphasised: "Guided by our vision of providing world-class healthcare, Abu Dhabi continues to adopt and implement the latest technologies to improve the health and well-being of our community and reinforce the emirate's position as a leading global healthcare destination.
"Robotic technologies and modern medical innovations, such as those now available at Tawam Hospital, are transforming care systems, harnessing the power of science and innovation to save and enhance lives."
Since introducing CyberKnife, Tawam Hospital has treated 23 patients, including the first case involving a prostate cancer patient. The technology enabled precise targeting of the tumour while preserving healthy surrounding tissues. The cases treated include seven prostate cancer patients, 12 brain tumour cases, three bone cancer cases, and one head and neck tumour case, highlighting a significant move towards non-invasive and effective cancer treatments.
CyberKnife operates by delivering high-dose, targeted radiation to cancer cells with extreme accuracy, eliminating the need for surgical incisions or complex procedures. It is particularly effective in treating tumours located in sensitive areas of the body, where traditional surgical methods may pose greater challenges or risks.
Saeed Jaber Al Kuwaiti, Group CEO of SEHA, noted, "This milestone reflects our unwavering commitment to delivering personalised, high-precision care that puts the patient first. By integrating advanced technologies like CyberKnife, we are improving outcomes, minimising treatment burdens, and enhancing the overall care experience. It is a clear step forward in our mission to continuously raise the standard of care and ensure every patient benefits from the most effective, evidence-based treatments available."
Rashed Al Qubaisi, Group Chief Operating Officer of PureHealth, stated, "The launch of CyberKnife is a powerful example of PureHealth's commitment to redefining the future of healthcare. This is more than a treatment innovation — it reflects our ambition to build a future-ready health system rooted in precision, innovation, and global excellence.
"By embedding advanced solutions like CyberKnife into national care pathways, we are not only enhancing outcomes at scale but also reinforcing the UAE's position as a global pioneer in next-generation healthcare."
Sign in with Google